Bank Julius Baer & Co. Ltd, Zurich Vaxart, Inc. Transaction History

Bank Julius Baer & Co. Ltd, Zurich

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 09, 2022	SELL	$4.29 - $6.64 $10,725 - $16,600	-2,500 Closed	0 $0
Q4 2021 Feb 15, 2022	SELL	$5.77 - $7.96 $150,020 - $206,960	-26,000 Reduced 91.23%	2,500 $16,000
Q3 2021 Nov 12, 2021	SELL	$6.67 - $9.8 $406,556 - $597,339	-60,953 Reduced 68.14%	28,500 $227,000
Q2 2021 Jul 23, 2021	SELL	$5.06 - $10.78 $35,652 - $75,955	-7,046 Reduced 7.3%	89,453 $670,000
Q1 2021 May 10, 2021	BUY	$5.64 - $23.33 $264,724 - $1.1 Million	46,937 Added 94.7%	96,499 $584,000
Q4 2020 Feb 24, 2021	BUY	$3.5 - $7.98 $151,882 - $346,292	43,395 Added 703.66%	49,562 $283,000
Q4 2020 Feb 12, 2021	SELL	$3.5 - $7.98 $209,408 - $477,451	-59,831 Reduced 90.66%	6,167 $283,000
Q3 2020 Nov 10, 2020	SELL	$4.78 - $16.97 $647,694 - $2.3 Million	-135,501 Reduced 67.25%	65,998 $439,000
Q2 2020 Aug 12, 2020	SELL	$1.68 - $8.85 $69,316 - $365,151	-41,260 Reduced 17.0%	201,499 $1.78 Million
Q1 2020 May 13, 2020	BUY	$0.34 - $2.87 $82,538 - $696,718	242,759 New	242,759 $432,000

108

37.9M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $93.6M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.